BRCA-associated Ovarian Cancer: from Molecular Genetics to Risk Management

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Aug 20

PMID 25136623

Citations 28

Authors

Giulia Girolimetti

Anna Myriam Perrone

Donatella Santini

Elena Barbieri

Flora Guerra

Simona Ferrari

Claudio Zamagni

Pierandrea De Iaco

Giuseppe Gasparre

Daniela Turchetti

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) mostly arises sporadically, but a fraction of cases are associated with mutations in BRCA1 and BRCA2 genes. The presence of a BRCA mutation in OC patients has been suggested as a prognostic and predictive factor. In addition, the identification of asymptomatic carriers of such mutations offers an unprecedented opportunity for OC prevention. This review is aimed at exploring the current knowledge on epidemiological and molecular aspects of BRCA-associated OC predisposition, on pathology and clinical behavior of OC occurring in BRCA mutation carriers, and on the available options for managing asymptomatic carriers.

Citing Articles

Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview.

Silvestris E, Cormio G, Loizzi V, Corrado G, Arezzo F, Petracca E Life (Basel). 2024; 14(5).

PMID: 38792636 PMC: 11122448. DOI: 10.3390/life14050615.

EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer.

McDevitt T, Durkie M, Arnold N, Burghel G, Butler S, Claes K Eur J Hum Genet. 2024; 32(5):479-488.

PMID: 38443545 PMC: 11061103. DOI: 10.1038/s41431-023-01507-5.

Uncovering the clinical relevance of unclassified variants in DNA repair genes: a focus on negative Tunisian cancer families.

Boujemaa M, Nouira F, Jandoubi N, Mejri N, Bouaziz H, Charfeddine C Front Genet. 2024; 15:1327894.

PMID: 38313678 PMC: 10834681. DOI: 10.3389/fgene.2024.1327894.

SPOCK1 Overexpression Suggests Poor Prognosis of Ovarian Cancer.

Vancza L, Horvath A, Seungyeon L, Rokusz A, Dezso K, Reszegi A Cancers (Basel). 2023; 15(7).

PMID: 37046698 PMC: 10093273. DOI: 10.3390/cancers15072037.

BRCA Mutations-The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers.

Loboda A, Adonin L, Zvereva S, Guschin D, Korneenko T, Telegina A Int J Mol Sci. 2023; 24(5).

PMID: 36902416 PMC: 10003548. DOI: 10.3390/ijms24054982.

References

Augustyn A, Agostino N, Namey T, Nair S, Martino M . Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities. Breast Cancer Res Treat. 2011; 129(2):629-34. DOI: 10.1007/s10549-011-1597-9. View

Risch H, McLaughlin J, Cole D, Rosen B, Bradley L, Fan I . Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006; 98(23):1694-706. DOI: 10.1093/jnci/djj465. View

Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M . High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol. 2007; 108(2):433-7. DOI: 10.1016/j.ygyno.2007.09.035. View

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

DAmours D, Desnoyers S, DSilva I, Poirier G . Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999; 342 ( Pt 2):249-68. PMC: 1220459. View

De Leeneer K, Coene I, Crombez B, Simkens J, Van den Broecke R, Bols A . Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Res Treat. 2011; 132(1):87-95. DOI: 10.1007/s10549-011-1544-9. View

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Beiner M, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P . The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2006; 104(1):7-10. DOI: 10.1016/j.ygyno.2006.08.004. View

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

10.

Deng C, Scott F . Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene. 2000; 19(8):1059-64. DOI: 10.1038/sj.onc.1203269. View

11.

Werness B, Ramus S, Whittemore A, Garlinghouse-Jones K, Oakley-Girvan I, DiCioccio R . Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol. 2000; 31(11):1420-4. View

12.

Monteiro A . BRCA1: exploring the links to transcription. Trends Biochem Sci. 2000; 25(10):469-74. DOI: 10.1016/s0968-0004(00)01632-7. View

13.

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A . Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-40. DOI: 10.1016/S1470-2045(09)70026-9. View

14.

Welcsh P, King M . BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001; 10(7):705-13. DOI: 10.1093/hmg/10.7.705. View

15.

Ben david Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck B, Beller U . Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002; 20(2):463-6. DOI: 10.1200/JCO.2002.20.2.463. View

16.

Paull T, Rogakou E, Yamazaki V, Kirchgessner C, Gellert M, Bonner W . A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 2000; 10(15):886-95. DOI: 10.1016/s0960-9822(00)00610-2. View

17.

Janezic S, Ziogas A, Krumroy L, Krasner M, Plummer S, Cohen P . Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Mol Genet. 1999; 8(5):889-97. DOI: 10.1093/hmg/8.5.889. View

18.

Goldgar D, Easton D, Byrnes G, Spurdle A, Iversen E, Greenblatt M . Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat. 2008; 29(11):1265-72. PMC: 2936773. DOI: 10.1002/humu.20897. View

19.

Vallee M, Francy T, Judkins M, Babikyan D, Lesueur F, Gammon A . Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat. 2011; 33(1):22-8. PMC: 3478957. DOI: 10.1002/humu.21629. View

20.

Finch A, Beiner M, Lubinski J, Lynch H, Moller P, Rosen B . Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006; 296(2):185-92. DOI: 10.1001/jama.296.2.185. View